DURHAM, N.C., Sept. 20, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte ® perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.
U.S. Navy Broadens CRADA With Oxygen Biotherapeutics To Include Preclinical Studies Assessing Oxycyte(R) For Spinal Cord Injury Due To Decompression Sickness And For Hemorrhagic Shock
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.